A Randomised, Double-blind, Placebo-controlled, Multi-centre, Sequential Phase II, and Phase III Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of AZD0780 Administered for up to 52 Weeks in Participants With Dyslipidaemia
Latest Information Update: 24 May 2025
At a glance
- Drugs AZD 0780 (Primary) ; Rosuvastatin
- Indications Dyslipidaemias
- Focus Pharmacokinetics; Registrational; Therapeutic Use
- Sponsors AstraZeneca
Most Recent Events
- 02 Apr 2025 Planned number of patients changed from 60 to 300.
- 02 Apr 2025 Planned End Date changed from 26 Jun 2025 to 18 Jun 2027.
- 02 Apr 2025 Planned primary completion date changed from 26 Jun 2025 to 18 Jun 2027.